Background Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some
patients treated with nintedanib experience weight loss. Exploratory data suggest that low …

Rationale There is no consensus as to when treatment for idiopathic pulmonary fibrosis (IPF)
should be initiated. Some physicians prefer not to treat patients with preserved lung volume …

Background Phase 3 trials have shown that nintedanib reduces the decline in forced vital
capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with …

Abstract Background In the INPULSIS® trials, nintedanib reduced the annual rate of decline
in forced vital capacity (FVC) versus placebo, consistent with slowing of disease …

Background: Nintedanib slows disease progression in patients with Idiopathic Pulmonary
Fibrosis (IPF) by reducing decline in Forced Vital Capacity (FVC). The effects of nintedanib …

In the Phase III INPULSIS® trials, nintedanib reduced the annual rate of decline in forced
vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). We …

Rationale: In the two replicate, placebo-controlled, 52-week, phase III INPULSIS trials,
nintedanib 150 mg twice daily significantly reduced the annual rate of decline in FVC, the …

Background Idiopathic pulmonary fibrosis (IPF) predominantly affects individuals aged> 60
years who have several comorbidities. Nintedanib is an approved treatment for IPF, which …

Background and objective In the two‐replicate randomized Phase III INPULSIS® trials in
patients with idiopathic pulmonary fibrosis (IPF), nintedanib 150 mg bd significantly reduced …

Background The two 52-week INPULSIS trials investigated nintedanib versus placebo in
patients with IPF, FVC≥ 50% predicted and DLco 30–79% predicted. The 24-week …